On Day 3 the 2025
European Alliance of Associations for Rheumatology (EULAR) congress, the focus shifted to abstract sessions. These are fast paced presentations where researchers share early findings from studies that are shaping where care may go next. Each speaker had about ten minutes to walk through their data, and while that sounds brief, there were several important takeaways that are especially relevant for people living with rheumatoid arthritis (RA) or those at high risk of developing it.
A major theme across these abstracts was prevention or more accurately, early intervention. Researchers are continuing to ask an important question: can treating people earlier change how RA develops over time?
Can early treatment delay rheumatoid arthritis?
One of the most talked about studies looked at people considered high risk for RA, especially those who may later become difficult to treat - which is defined as disease that does not respond after failing two biologics with the same mechanism of action, such as two TNF inhibitors. This trial compared six months of treatment with abatacept, also known as Orencia, against a placebo.
What stood out was that while RA was not fully prevented,
early treatment significantly delayed the onset of RA. The delay ranged from about 10 months to as long as five years for some participants. That may not sound like prevention in the strict sense, but for patients, gaining years without active disease can be incredibly meaningful.
Researchers also noted an important pattern. People who developed RA earlier in the study experienced:
- More pain
- Higher levels of inflammation
- Worse health related quality of life
These patients tended to fall into the difficult to treat category. While this group was smaller overall, the findings reinforce how valuable early intervention could be for those most at risk of aggressive disease.
Do lifestyle risk factors affect how fast RA shows up?
Another abstract came from a Swedish study that asked a different but related question. Researchers wanted to know whether known RA risk factors like smoking and obesity influence how quickly RA develops once symptoms begin.
They looked at individuals diagnosed with RA within one year of their first symptoms and analyzed whether these risk factors sped up disease onset. Surprisingly, the study found
no strong association between smoking or obesity and the speed at which RA became clinically apparent.
It is important to note what this study did not include. Researchers did not factor in ACPA status or other autoantibody profiles, which we know can play a significant role in disease severity and progression. This study looked at the person as a whole rather than diving into immune markers, which may explain why some expected associations were not seen.
Predicting lung disease progression in RA
The third abstract focused on a serious but often under discussed complication: interstitial lung disease associated with rheumatoid arthritis, also known as RA ILD.
In this study, researchers developed a
prediction model using clinical features and blood based biomarkers specific to both RA and lung disease. Their goal was to identify who is most likely to experience progression of RA ILD.
The model successfully stratified patients into low, moderate, and high risk groups. One of the most striking findings was that
about 80 percent of patients identified as high risk were correctly predicted to experience disease progression. On the flip side, the low risk group had a strong negative predictive value, meaning they were unlikely to worsen quickly.
Why does this matter? Because it supports more personalized care. High risk patients may benefit from earlier or more aggressive treatment, while low risk patients could be monitored more carefully without unnecessary intervention. This approach has the potential to improve outcomes while also addressing cost effectiveness, something researchers openly acknowledged as an important part of real world care.
Key takeaways for patients
While these were early studies, they point to some encouraging trends:
- Early treatment may meaningfully delay RA onset in high risk individuals
- Faster RA progression is not always tied to common lifestyle risk factors
- Predictive models can help identify who needs closer monitoring or earlier treatment
- Personalized, risk based care continues to be a growing focus in rheumatology
Abstract sessions often give us a glimpse of what is coming next. These studies suggest that the future of RA care is less about one size fits all and more about understanding individual risk, timing, and long term outcomes.
As always, these findings are not meant to replace personal medical advice, but they do offer reassurance that researchers are actively working to improve how RA is detected, monitored, and treated earlier in the disease course.
Learn more about
RA and ILD.
